Abstract
Parotid gland cancer is a rare disease, having various histological types and malignancy, and may be difficult to diagnose and treat. We investigated 41 cases of parotid gland cancer who underwent surgery as the first-line treatment in our department. The 5-year crude survival rate was 90.2%, the 5-year recurrence-free survival rate was 84.6%, and the prognostic factors that showed a significant difference in multivariate analysis were the presence or absence of cervical lymph node metastasis. Since cervical lymph node metastasis was observed in 5 of 9 cases who underwent prophylactic neck dissection, such dissection should be considered in cases of suspected locally advanced cancer or high-grade cancer. Trastuzumab therapy has been effective in cases of recurrence of lung metastasis. Further knowledge of chemotherapy for inoperable cases and distant metastasis cases needs to be accumulated.
